Orion invites analysts and media to Financial Statement Release conference on Tuesday 5 February 2013

22 januari 2013 ORION CORPORATION STOCK EXCHANGE RELEASE 22 JANUARY 2013 at 10.00 AM EET Orion will publish its Financial Statement Release for 2012 on Tuesday, 5 February 2013 approximatelyat 12:00 Finnish time (EET). The release and related presentation material in Finnish and in English will be available on the Group's homepage at www.orion.fi/en/investors promptly after the publishing. News conference for analysts and media on Tuesday 5 February 2013 at 13:30 EET A news conference for analysts and media will be held on Tuesday 5 February 2013 at 13:30 EET at Hotel Kämp, address Pohjoisesplanadi 29, Helsinki. President and CEO Timo Lappalainen will give a brief presentation in English on the financial review. Live webcast and conference call The event can be followed live as a webcast accessible at http://qsb.webcast.fi/o/orion/orion_2013_0205_q4/ Questions can be asked also through conference call lines after the result presentation. The conference call ID is 927 747 and the phone numbers to participate the conference are: when calling from the United States +1 866 803 8344 when calling from other countries +44 (0)20 7162 0125 News conference recordings A recording of the event in English and a recording of the presentation by the President and CEO in Finnish will be available on the Orion website later the same day. Silent period The silent period preceding the publication is ongoing and continues until the disclosure. Orion Corporation Timo Lappalainen Jari Karlson President and CEO CFO Publisher: Orion Corporation Communications Orionintie 1A, FI-02200 Espoo www.orion.fi Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler(®) pulmonary drugs. Orion's net sales in 2011 amounted to EUR 918 million and the company had about 3,400 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki. This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Orion Oyj via Thomson Reuters ONE [HUG#1672063]